Adaptimmune

Adaptimmune is committed to designing and delivering cell therapies to transform the lives of people living with cancer. We have reported clinical responses in multiple solid tumors with our engineered T- cell therapies (called SPEAR T-cells), and we have a deep preclinical pipeline of additional cell therapy products and approaches to enable us to deliver on our mission. We are world leaders with proprietary technology that enables us to engineer T-cell receptors (TCRs) to target tumors. We precisely tune these receptors to attack specific solid tumors, which has led to deep and durable clinical responses in a range of indications. TCRs recognize proteins that are presented on the cell surface in the antigen presentation machinery called human leukocyte antigen (HLA). The current clinical pipeline is restricted to patients who are HLA-02 positive. Our lead program targets a cancer antigen called MAGE-A4, which is expressed on a broad range of solid tumors. We have reported clinical responses in synovial sarcoma, lung, head and neck, and gastroesophageal cancers with our MAGE-A4 targeted SPEAR T-cells. We intend to file our first BLA for afamitresgene autoleucel, our first therapy targeting MAGE-A4, in 2022 using the data from the Phase 2 trial SPEARHEAD-1. We will present initial data about SPEARHEAD-1 at this year’s 2021 ASCO Annual Meeting. We are also applying TCR engineering and enhancement expertise to developing new cell therapy products, including next-generation SPEAR T-cells, TCRs targeted to additional HLA types, HLA independent TCRs (HiTs), and next-generation tumor infiltrating lymphocytes (TILs). Our deep preclinical pipeline of products is designed to reach more cancer targets, broader patient populations, and achieve deeper and more durable responses. We are also developing an “off-the-shelf” or allogeneic cell therapy platform, which would make our therapies available “on demand” for patients who need them.
... More Info Less Info

Our Phase 1 and 2 clinical trials are open-label and utilize an autologous approach, which require harvest of a patient’s own T-cells. After harvest, we introduce an engineered and affinity enhanced TCR into the patient’s T-cells to target cancer. The engineered specific peptide enhanced affinity receptor (SPEAR) T-cells are then given back to the patient.We completed enrollment in our Phase 1 trial with afamitresgene autoleucel (afami-cel, formerly ADP A2M4) and reported results at ASCO 2020. Based on compelling data from this trial in patients with synovial sarcoma, we initiated our Phase 2 SPEARHEAD-1 trial. We will present initial data from SPEARHEAD-1 at ASCO this year (abstract # 11504) in an oral presentation on June 4th. We plan to file a BLA in 2022 for afami-cel to be used to treat people with synovial sarcoma. We have also developed a next-generation SPEAR T-cell product targeting MAGE-A4 incorporating a CD8α element to increase potency (ADP-A2M4CD8). We are currently enrolling patients with multiple solid tumor indications in our Phase 1 SURPASS trial with this next-generation SPEAR T-cell therapy. The trial is running at various centers in Canada, Spain, and the US.We are also recruiting patients into a Phase 1 trial with an engineered TCR targeting a cancer antigen called AFP that is expressed in liver cancer. We reported a complete response with this therapy, ADP A2AFP (ILC 2020). We are continuing to enroll new patients in this trial, conducted in Canada, France, Spain, the UK, and the US.... More Info Less Info